146 related articles for article (PubMed ID: 36825538)
1. Timing of CAR-T therapy in follicular lymphoma.
Alhaj Moustafa M
Expert Rev Anticancer Ther; 2023 Apr; 23(4):347-349. PubMed ID: 36825538
[No Abstract] [Full Text] [Related]
2. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
[TBL] [Abstract][Full Text] [Related]
3. [Research progress of CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma].
Yang JJ; Sang W; Xu KL
Zhonghua Nei Ke Za Zhi; 2019 Nov; 58(11):849-852. PubMed ID: 31665867
[TBL] [Abstract][Full Text] [Related]
4. CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma.
Gideon J
Clin J Oncol Nurs; 2022 Nov; 26(6):597-601. PubMed ID: 36413724
[TBL] [Abstract][Full Text] [Related]
5. CAR T cell therapy for B-cell lymphomas.
Chavez JC; Locke FL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
[TBL] [Abstract][Full Text] [Related]
7. [CAR-T cells in lymphomas: Current and evolving role].
Messéant O; Houot R
Bull Cancer; 2021 Oct; 108(10S):S28-S39. PubMed ID: 34920805
[TBL] [Abstract][Full Text] [Related]
8. CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview.
Mohty M; Dulery R; Gauthier J; Malard F; Brissot E; Aljurf M; Bazarbachi A; Chabanon C; Kharfan-Dabaja MA; Savani BN; Huang H; Kenderian SS; Perales MA; Yakoub-Agha I; Nagler A
Bone Marrow Transplant; 2020 Aug; 55(8):1525-1532. PubMed ID: 32305998
[TBL] [Abstract][Full Text] [Related]
9. Significant response of patients with transformed follicular lymphoma with rapid disease progression to CAR-T therapy.
Hirano T; Tatetsu H; Ueno S; Shichijo T; Furukawa S; Tsujihashi M; Miyakawa T; Shiraishi S; Higuchi Y; Uchiba M; Yasunaga JI; Nosaka K; Matsuoka M
J Clin Exp Hematop; 2023 Dec; 63(4):266-269. PubMed ID: 38030235
[No Abstract] [Full Text] [Related]
10. Understanding the Etiology of Pancytopenias in the CAR T-Cell Therapy Setting: What We Know and What We Don't?
Yassine F; Murthy H; Ghabashi E; Kharfan-Dabaja MA; Iqbal M
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):122-130. PubMed ID: 36633964
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
Mihăilă RG
Recent Pat Anticancer Drug Discov; 2019; 14(4):312-323. PubMed ID: 31642414
[TBL] [Abstract][Full Text] [Related]
12. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Chow VA; Shadman M; Gopal AK
Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
[TBL] [Abstract][Full Text] [Related]
13. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
14. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
St-Pierre F; Gordon LI
Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471
[TBL] [Abstract][Full Text] [Related]
15. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
17. [Diffuse large B-cell lymphoma: a revolutionary treatment based on genetically-modified immune cells called CAR T cells].
Maquet C; Beguin Y; De Prijck B; Willems E; Servais S; Bonnet C
Rev Med Liege; 2021 May; 76(5-6):476-481. PubMed ID: 34080383
[TBL] [Abstract][Full Text] [Related]
18. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
19. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Bartlett NL; Caimi PF; Chang JE; Chavez JC; Christian B; Fayad LE; Glenn MJ; Habermann TM; Lee Harris N; Hernandez-Ilizaliturri F; Kaminski MS; Kelsey CR; Khan N; Krivacic S; LaCasce AS; Mehta A; Nademanee A; Rabinovitch R; Reddy N; Reid E; Roberts KB; Smith SD; Snyder ED; Swinnen LJ; Vose JM; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2019 Jun; 17(6):650-661. PubMed ID: 31200358
[TBL] [Abstract][Full Text] [Related]
20. [New European approvals: Tisagenlecleucel and Axicabtagene ciloleucel CAR-T cells - Follicular lymphoma after at least two and three prior lines of therapy].
Cordeil S; Bachy E
Bull Cancer; 2022 Nov; 109(11):1106-1108. PubMed ID: 36088178
[No Abstract] [Full Text] [Related]
[Next] [New Search]
